Neos Therapeutics Inc (NASDAQ:NEOS) has earned a consensus rating of “Buy” from the eight brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $15.25.

A number of analysts have commented on NEOS shares. Zacks Investment Research lowered Neos Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 12th. Cantor Fitzgerald set a $20.00 target price on Neos Therapeutics and gave the stock a “buy” rating in a report on Wednesday, November 1st. Wells Fargo & Company set a $14.00 target price on Neos Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 18th. Cowen and Company reissued a “buy” rating on shares of Neos Therapeutics in a report on Thursday, October 26th. Finally, Royal Bank Of Canada set a $12.00 target price on Neos Therapeutics and gave the stock an “outperform” rating in a report on Tuesday, August 8th.

Institutional investors and hedge funds have recently modified their holdings of the stock. State of Wisconsin Investment Board bought a new stake in shares of Neos Therapeutics in the second quarter worth $102,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Neos Therapeutics in the second quarter worth $110,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Neos Therapeutics in the second quarter worth $118,000. New York State Common Retirement Fund grew its holdings in shares of Neos Therapeutics by 67.3% in the third quarter. New York State Common Retirement Fund now owns 17,400 shares of the company’s stock worth $159,000 after acquiring an additional 7,000 shares during the period. Finally, Tudor Investment Corp ET AL bought a new stake in shares of Neos Therapeutics in the second quarter worth $146,000. 44.53% of the stock is owned by institutional investors.

Neos Therapeutics (NASDAQ:NEOS) opened at $10.43 on Wednesday. Neos Therapeutics has a 52-week low of $4.85 and a 52-week high of $13.15. The company has a debt-to-equity ratio of 2.33, a current ratio of 3.04 and a quick ratio of 2.84.

Neos Therapeutics (NASDAQ:NEOS) last posted its earnings results on Tuesday, August 8th. The company reported ($0.83) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.83). The business had revenue of $4.91 million during the quarter. Neos Therapeutics had a negative return on equity of 394.99% and a negative net margin of 380.40%. equities analysts anticipate that Neos Therapeutics will post -3.02 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Neos Therapeutics Inc (NEOS) Receives Average Rating of “Buy” from Brokerages” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/11/08/neos-therapeutics-inc-neos-receives-average-rating-of-buy-from-brokerages.html.

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Analyst Recommendations for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.